Celltrion's autoimmune disease biosimilar lands in S. Korea
By Kim Han-joo
SEOUL, March 2 (Yonhap) -- South Korean pharmaceutical giant Celltrion Inc. said Wednesday that its autoimmune disease biosimilar Yuflyma has begun sales in the domestic market.
Yuflyma -- a biosimilar referencing blockbuster drug Humira by AbbVie Inc. -- is used to treat patients with multiple chronic inflammatory diseases, such as rheumatoid arthritis and psoriasis.
This image, provided by South Korean pharmaceutical giant Celltrion Inc., shows its biosimilar Yuflyma (PHOTO NOT FOR SALE) (Yonhap)
The high-concentration biosimilar is already being marketed in major European countries following its approval from drug authorities last year.
Yuflyma requires only half the solution administered to patients compared with the existing Humira biosimilar and is also citrate-free, which lessens discomfort during injection, Celltrion said.
Yuflyma is priced at around 245,000 won (US$203) per dose in South Korea, which is similar to other biosimilars of Humira, but patients with cancer or other kinds of rare diseases will only pay one-tenth of the cost.
khj@yna.co.kr
(END)
-
(LEAD) (News Focus) Abrupt replacement of national security adviser gives rise to much speculation -
(2nd LD) N. Korea plans to send weapons, munitions to Russia in exchange for food: NSC -
Grandson of ex-President Chun released after investigation over drug use -
S. Korea releases report on N. Korea's human rights violations -
National Assembly consents to arrest of PPP lawmaker Ha
-
(News Focus) Abrupt replacement of national security adviser gives rise to much speculation
-
Yoon puts S. Korea-Japan relations back on track -
Japan's removal of export curbs on S. Korea to boost supply chain stability, ease biz uncertainties -
Yoon's summit with Biden to highlight S. Korea's 'pivotal' role in region: U.S. experts -
(News Focus) Solution to forced labor issue shows Yoon's commitment to improving ties with Japan
